...
首页> 外文期刊>Angiology: the Journal of Vascular Diseases >Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.
【24h】

Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.

机译:短期大剂量阿托伐他汀对冠状动脉造影患者预防造影剂诱发的肾病的疗效。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Contrast-induced nephropathy (CIN) is associated with increased morbidity, extended hospital stay, and higher costs. We compared an atorvastatin plus N-acetylcysteine (NAC) regimen with NAC alone in patients undergoing coronary angiography. A total of 130 patients (mean age 54 +/- 10; 77 men) undergoing coronary angiography were studied. Seven CIN cases occurred in the NAC group and 2 in the atorvastatin + NAC group; this difference was not significant. Baseline mean creatinine and estimated glomerular filtration rate (eGFR) were similar between the 2 groups, whereas after the procedure there was a significant creatinine decrease and eGFR increase in the atorvastatin + NAC group. Change in creatinine (baseline creatinine-creatinine after the procedure) was also significantly higher in patients taking statin plus NAC. Atorvastatin may be effective in protecting patients undergoing coronary angiography from CIN.
机译:造影剂诱发的肾病(CIN)与发病率增加,住院时间延长和费用增加有关。我们在接受冠状动脉造影的患者中比较了阿托伐他汀加N-乙酰半胱氨酸(NAC)方案与单独NAC的方案。共研究了130例接受冠状动脉造影的患者(平均年龄54 +/- 10; 77名男性)。 NAC组发生7例CIN,阿托伐他汀+ NAC组发生2例;这种差异并不明显。两组之间的基线平均肌酐和估计的肾小球滤过率(eGFR)相似,而阿托伐他汀+ NAC组的术后肌酐明显降低,eGFR升高。服用他汀+ NAC的患者的肌酐变化(基线后的肌酐-肌酐)也明显更高。阿托伐他汀可能有效地保护接受冠状动脉造影的患者免于CIN。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号